CD19 and neoplasm: Several CAR T cell platforms, including CD19 CAR [93, 94] and CD38 CAR [95], successfully incorporated the Tet-ON system and demonstrated dose-dependent Dox-induced CAR expression and anti-tumor activity in vitro and in vivo.